WHO To Assess Quality Of Biosimilar Products To Fill Regulatory Gap
Reuters: Gap in regulating biotech drug copies prompts WHO to step in
“Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike — but uneven regulation has created a lopsided market. Now the World Health Organization (WHO) is stepping in to assess the quality of such so-called biosimilars, offering a global stamp of approval that could make them more widely available, while also raising the quality bar…” (Hirschler/Siddiqui, 5/30).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.